Stock Analiz

Nephros Inc. NEPH

Medical/Dental Instruments · data as of November 13, 2026

$3.05Market cap $33M
Open the interactive analysis →

Nephros Inc. (NEPH) is a healthcare company listed in the US with a market value of about $33M. In the twelve months to September 30, 2026 it had revenue of $22M and net income of $2M, a net margin of 8.9%.

Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is track record (1/5).

Key numbers: a P/E of 16.9, 5-year revenue growth of 17% a year, a 5-year average ROIC of -15%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 78% below the current price.

About Nephros

Nephros is listed in the US and classified in medical/dental instruments. Revenue went from $2M in 2014 to $19M in 2025, growth of about 24.1% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 7% over three years (dilution for shareholders). It spends 7% of revenue on research and development.

Score: 2.2 / 5

Value2/5
Future growth4/5
Track record1/5
Financial health3/5
Shareholder returns1/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row
  • ROE above 15%

Valuation

P/E (TTM)16.9
Forward P/E—
P/FCF—
P/S1.5
P/B2.6
EV/EBITDA15.2
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−78%

Growth and quality

Revenue growth (1 yr)32.7%
Revenue growth (5 yrs, per year)17.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-23.2%
ROIC (5-yr avg.)-15.4%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$22M$19M$14M$14M$10M$10M$9M$10M$6M$4M$2M
Net income$2M$1M$74000-$2M-$7M-$4M-$5M-$3M-$3M-$809000-$3M
Free cash flow——-$547000$752000-$3M-$1M-$7M-$2M——-$2M
EPS (diluted)$0.18$0.11$0.01$-0.15$-0.73$-0.41$-0.52$-0.45$-0.50$-0.18$-0.54
Net margin8.9%6.3%0.5%-11.1%-74.0%-37.9%-52.9%-30.8%-59.8%-21.2%-130.7%
ROIC—10.1%0.1%-15.6%-51.3%-20.2%-23.8%-42.1%-52.1%-48.6%-150.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Nephros’s P/E ratio?

About 16.9, based on the last twelve months of diluted earnings per share.

Is Nephros stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 78% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Nephros pay a dividend?

Not currently.

Is Nephros a good stock to buy?

We do not give buy or sell advice. Nephros scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.